Development, Exclusivity And Option Products Agreement (Details) $ in Millions |
6 Months Ended |
|---|---|
|
Jun. 30, 2021
USD ($)
| |
| Development Exclusivity And Option Products Agreement [Abstract] | |
| Agreement, description | Pursuant to the Agreement, CollPlant granted to AbbVie and its affiliates, a license and worldwide exclusive rights to use its rhCollagen, for the production and commercialization of dermal and soft tissue filler products ("Exclusive Products"). With respect to the license, CollPlant received a $14 million upfront cash payment and is entitled to receive up to additional $36 million in proceeds upon the achievement of certain development, clinical trial, regulatory and commercial sale milestones. |
| Upfront cash payment | $ 14 |
| Commercial sale milestones | $ 36 |
| Commercial sale | 10 years |
| Written notice period | 60 days |
| Estimated transaction price | $ 14 |
| X | ||||||||||
- Definition Commercial sale. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Upfront Cash payment. No definition available.
|
| X | ||||||||||
- Definition Written notice period. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in standardized measure of discounted future net cash flow as a result of change in estimated future development costs. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of additional paid-in capital (APIC) classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|